HSA Singapore Announcements

Welcome Speech at 80th Anniversary of National Blood Programme

HSA CEO Adj Prof (Dr) Raymond Chua delivered a welcome speech at the 80th anniversary of Singapore's National Blood Programme. The speech recognises donors, partners, and volunteers who have contributed to the programme since its establishment, as well as the ongoing partnership with the Singapore Red Cross. HSA's Blood Services Group and laboratory staff are commended for maintaining internationally recognised standards in transfusion medicine.

Singapore National Blood Programme Marks 80 Years

The Health Sciences Authority (HSA) and Singapore Red Cross marked the 80th anniversary of the National Blood Programme at a commemorative event. Minister for Health Ong Ye Kung announced new donor recognition initiatives including a Healthpoints programme launching in H2 2026 and the '80 for 80' Blood Donation Marathon to encourage corporate blood donation drives. HSA projects Singapore's blood demand could outstrip supply by 2035 as youth donations have declined by more than half over the past decade.

New Drug Approvals February 2026

The Health Sciences Authority (HSA) Singapore announced new therapeutic product approvals granted in February 2026. The announcement lists newly approved therapeutic products and new indications approved for registered therapeutic products. Healthcare professionals and industry members are directed to the listing for details.

18-year-old charged for alleged trafficking of etomidate vaporiser pods

HSA charged an 18-year-old male in Singapore court on 6 April 2026 for alleged trafficking of etomidate vaporiser pods. During an enforcement operation on 4 April, HSA officers seized 108 etomidate pods, one vaporiser, and duty-unpaid cigarettes. This is the second prosecution of an 18-year-old for etomidate trafficking, following enhanced penalties that took effect on 1 September 2025.

eCTD Format Acceptance and Quality Defect Declaration Requirements for Therapeutic Products

HSA Singapore announced that electronic Common Technical Document (eCTD) format will be officially accepted for therapeutic product regulatory dossier submissions effective 1 April 2026, using SG-HSA eCTD version 1.1. Additionally, applicants must provide an official declaration confirming no known quality defects in CMC dossiers for submissions from 1 June 2026 onward.

Famodine Tablet 20mg Recalled Due to Assay Test Result

The Health Sciences Authority (HSA) Singapore has initiated a retail-level recall of Famodine Tablet 20mg (famotidine) due to out-of-specification assay test results. The affected batch (232218) must be stopped from supply and returned to the company.

HSA Seized Over 1 Million Illegal Health Products in 2025

Singapore's Health Sciences Authority (HSA) reported seizing over 1 million illegal health products in 2025, a 10% increase from the previous year. The agency also removed 2,358 online listings, a significant decrease from previous years due to increased surveillance and collaboration with platforms. The enforcement actions targeted cough syrups, sexual enhancement medicines, and sedatives.

NARSskin Night Treatment Recalled Due to Sudan IV Detection

The Health Sciences Authority (HSA) of Singapore has initiated a retail-level recall for all batches of NARSskin light reflecting restorative night treatment. The product was found to contain Sudan IV, a substance not permitted in cosmetic products, during a quality surveillance program. Local company Shiseido Singapore Co. (Pte) Limited is instructed to stop supplying the product and return existing stocks.

HSA Singapore: Adverse Effects from Banned Medicinal Products

HSA Singapore has issued a notice regarding adverse effects reported after consumers took banned medicinal products. The agency is highlighting the risks associated with using unapproved health products and urges consumers to exercise caution.

HSA Singapore New Drug Approvals - January 2026

HSA Singapore announced new drug approvals for January 2026. This notice serves to inform stakeholders of the latest additions to the approved drug list.

Keynote on Longevity Innovation, Regulation, and Collaboration

The Health Sciences Authority (HSA) of Singapore has published the text of a keynote address discussing innovation in longevity, the regulatory landscape, and the importance of collaboration. The speech highlights the evolving field of longevity and the need for regulatory frameworks to keep pace with scientific advancements.

HSA Singapore SG-eCTD Version 1.1 Package Update

The Health Sciences Authority (HSA) of Singapore has released an updated package for SG-eCTD version 1.1. This update pertains to the electronic Common Technical Document submission format used for regulatory filings.

HSA Warns Public About Products with Banned or Potent Medicinal Ingredients

The Health Sciences Authority (HSA) in Singapore has issued a warning regarding four products found to contain banned or potent medicinal ingredients, including steroids and sibutramine. Three consumers experienced serious adverse effects after consuming these products. HSA is working to remove listings and investigate sellers.

HSA Seizes Over $1.1M in Vaporisers

The Health Sciences Authority (HSA) seized over $1.1 million worth of vaporisers in an operation on February 24, 2026. New penalties under the Tobacco and Vaporisers Control Act (TVCA) will take effect from May 1, 2026, targeting importers, suppliers, and premises owners.

Raymond Chua's address at 29th Medical Device Regulators Forum

Raymond Chua's address at 29th Medical Device Regulators Forum

Therapeutic Product Approvals and Indications List Update

The Health Sciences Authority (HSA) of Singapore has published updated lists of new therapeutic product approvals and new indications for registered therapeutic products, effective March 2026. These lists are intended for healthcare professionals and industry members.

HSA Deepens International Partnerships for Biomedical Sector Growth

The Health Sciences Authority (HSA) of Singapore has announced deepened collaborations with Malaysia and Uzbekistan to facilitate access to medicines and medical devices. These partnerships include a formalised Medical Device Regulatory Reliance Programme with Malaysia and a Memorandum of Understanding with Uzbekistan for broader regulatory cooperation.

HSA Charges Man for Trafficking Etomidate Vaporiser Pods

The Health Sciences Authority (HSA) of Singapore has charged a 34-year-old man for allegedly trafficking etomidate vaporiser pods. The charges follow an enforcement operation where HSA seized over 900 tablets, cough syrup, and etomidate-containing vaporiser pods. Stricter penalties for etomidate trafficking are in effect.

HSA Achieves WHO ML4 Recognition for Medical Devices, Expands Biomedical Role

The Health Sciences Authority (HSA) in Singapore has achieved the highest World Health Organization (WHO) Maturity Level (ML4) for medical devices regulatory systems, becoming the first national authority globally to do so. HSA is also expanding its economic role to support the biomedical sector's growth.